drugset / Trial / NCT01981668

The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation

NCT01981668

NaSingle-groupOpen-labelTreatment

Summary

This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the maximum tolerated dose(MTD) of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.

Timeline

Start
Primary completion
2013-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabazitaxel Other / unclassified

Indications